0000000000128932

AUTHOR

Alimuddin Zumla

showing 23 related works from this author

COVID-19 and tuberculosis - threats and opportunities

2020

Pulmonary and Respiratory Medicine2019-20 coronavirus outbreakEconomic growthTuberculosisCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralInternational Health RegulationsGlobal HealthInternational Health RegulationsBetacoronavirusPandemicGlobal healthMedicineHumansPandemicsTuberculosis PulmonaryHealth Services Needs and Demandbusiness.industryCoinfectionSARS-CoV-2COVID-19medicine.diseaseCoronavirusInfectious DiseasesCommunicable Disease ControlbusinessCoronavirus InfectionsCoronavirus Infections
researchProduct

World Tuberculosis Day 2021 Theme - 'THE CLOCK IS TICKING' - and the world is running out of time to deliver the United Nations General Assembly comm…

2021

Microbiology (medical)2019-20 coronavirus outbreakEconomic growthTuberculosisUnited NationsCoronavirus disease 2019 (COVID-19)General assemblySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Infectious and parasitic diseasesRC109-216Political sciencePandemicwc_505medicineHumansTuberculosisPandemicswa_105SARS-CoV-2COVID-19General Medicinemedicine.diseaseCoronavirusInfectious Diseaseswf_200Theme (narrative)
researchProduct

Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study…

2022

Funding: Bill & Melinda Gates Foundation. Background: The global burden of lower respiratory infections (LRIs) and corresponding risk factors in children older than 5 years and adults has not been studied as comprehensively as it has been in children younger than 5 years. We assessed the burden and trends of LRIs and risk factors across all age groups by sex, for 204 countries and territories.  Methods: In this analysis of data for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we used clinician-diagnosed pneumonia or bronchiolitis as our case definition for LRIs. We included International Classification of Diseases 9th edition codes 079.6, 466–469, 470.0, 480–4…

AdultMaleGlobal HealthTimeGlobal Burden of DiseaseSDG 3 - Good Health and Well-beingRisk FactorsRA0421RA0421 Public health. Hygiene. Preventive MedicineHumansAmbient air-qualityChildRespiratory Tract InfectionsAgedAged 80 and overMCCSex CharacteristicsMalnutritionPyridinolcarbamateBayes Theorem3rd-DAS3142 Public health care science environmental and occupational healthInfectious Diseases3121 General medicine internal medicine and other clinical medicineChild PreschoolFemaleParticulate MatterQuality-Adjusted Life YearsCovid-19LRI
researchProduct

Reducing mortality from 2019-nCoV: host-directed therapies should be an option

2020

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)business.industrySARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralImmunization PassiveCOVID-19General MedicineGlobal HealthArticleCOVID-19 Drug TreatmentBetacoronavirusDrug DiscoveryViral therapyMedicineHumansbusinessIntensive care medicineCoronavirus InfectionsHost (network)PandemicsCOVID-19 SerotherapyThe Lancet
researchProduct

Looking for pathways related to COVID-19 phenotypes: Confirmation of pathogenic mechanisms by SARS-CoV-2 - Host interactome

2020

AbstractIn the last months, many studies have clearly described several mechanisms of SARS-CoV-2 infection at cell and tissue level. Host conditions and comorbidities were identified as risk factors for severe and fatal disease courses, but the mechanisms of interaction between host and SARS-CoV-2 determining the grade of COVID- 19 severity, are still unknown.We provide a network analysis on protein–protein interactions (PPI) between viral and host proteins to better identify host biological responses, induced by both whole proteome of SARS-CoV-2 and specific viral proteins. A host-virus interactome was inferred on published PPI, using an explorative algorithm (Random Walk with Restart) tri…

Host (biology)Viral proteinvirusesCellComputational biologyBiologymedicine.disease_causePhenotypeInteractomePathogenesismedicine.anatomical_structureProteomemedicineViral Accessory Proteins
researchProduct

Clinical and Imaging Features of Adults with Recurrent Pulmonary Tuberculosis - A Prospective Case-Controlled Study

2021

Background: Recurrent pulmonary tuberculosis (RPTB) is a growing, important and neglected problem affecting treated TB patients and TB health services across the world, particularly in sub-Saharan Africa. Analyses and identification of differences in clinical features between recurrent PTB and newly diagnosed PTB may lead to improved management recommendations. Methods: Between September 1st 2019 and January 31st 2020, we performed a prospective case controlled study of clinical and imaging features of patients with recurrent pulmonary tuberculosis and compared them with those of newly diagnosed PTB cases. Recurrent PTB was defined as a patient with bacteriologically confirmed active PTB wh…

0301 basic medicineMicrobiology (medical)medicine.medical_specialty030106 microbiologyInfectious and parasitic diseasesRC109-216Lung injuryChest painLogistic regressionImagingClinical03 medical and health sciences0302 clinical medicinePulmonary tuberculosisInternal medicineHumansMedicine030212 general & internal medicineTuberculosis PulmonaryLung functionLungbusiness.industryAssociated factorsPulmonary tuberculosisCase-control studyGeneral MedicineInfectious Diseasesmedicine.anatomical_structureRadiological weaponmedicine.symptomRecurrentbusinessInternational Journal of Infectious Diseases
researchProduct

Host-directed therapies for COVID-19

2021

Purpose of review Severe acute respiratory syndrome coronavirus-2-induced hyperinflammation is a major cause of death or end-organ dysfunction in COVID-19 patients. We review adjunct host-directed therapies (HDTs) for COVID-19 management. Recent findings The use of umbilical cord-derived mesenchymal stem cells as HDT for COVID-19 has been shown to be safe in phase 1 and 2 trials. Trials of anti-interleukin-6 receptor antibodies show promising mortality benefit in hospitalized COVID-19 patients. Repurposed drugs and monoclonal antibodies targeting specific cytokines acting on different aspects of the pro- and anti-inflammatory cascades are under evaluation. Summary A range of HDTs shows prom…

InflammationPulmonary and Respiratory Medicine2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)SARS-CoV-2medicine.drug_classbusiness.industryMesenchymal stem cellCOVID-19InflammationLong term disabilityMesenchymal Stem Cell TransplantationBioinformaticsMonoclonal antibodymedicineHumansImmunologic FactorsIn patientMolecular Targeted Therapymedicine.symptombusinessCause of deathCurrent Opinion in Pulmonary Medicine
researchProduct

COVID-19 disease - Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and manageme…

2020

Background Detailed temporal analyses of complete (full) blood count (CBC) parameters, their evolution and relationship to patient age, gender, co-morbidities and management outcomes in survivors and non-survivors with COVID-19 disease, could identify prognostic clinical biomarkers. Methods From 29 January 2020 until 28 March 2020, we performed a longitudinal cohort study of COVID-19 inpatients at the Italian National Institute for Infectious Diseases, Rome, Italy. 9 CBC parameters were studied as continuous variables [neutrophils, lymphocytes, monocytes, platelets, mean platelet volume, red blood cell count, haemoglobin concentration, mean red blood cell volume and red blood cell distribu…

Erythrocyte IndicesMaleViral DiseasesNeutrophilsPhysiologyclinical biomarkersRomeDisease030204 cardiovascular system & hematologyCardiovascular MedicineCohort StudiesLeukocyte CountWhite Blood Cells0302 clinical medicineMedical ConditionsAnimal CellsMedicine and Health SciencesRenal Failure030212 general & internal medicineLongitudinal StudiesLymphocytesSurvivorsCOPDMultidisciplinarymedicine.diagnostic_testQRComplete blood countMiddle AgedPrognosisBody FluidsInfectious DiseasesBloodSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAPhysiological Parameterscovid-19; blood cell count; clinical biomarkerscovid-19Cardiovascular DiseasesNephrologyMedicineFemaleCellular TypesAnatomyMean Platelet VolumeCohort studyResearch ArticlePlateletsmedicine.medical_specialtyScienceImmune CellsImmunologyCardiology03 medical and health sciencesInternal medicinemedicineHumansObesityMean platelet volumeDemographyInflammationBlood Cellsbusiness.industryBody WeightBiology and Life SciencesRed blood cell distribution widthCovid 19Cell Biologymedicine.diseaseObesityBlood CountsAnisocytosisblood cell countbusinessBiomarkers
researchProduct

Immune responses during COVID-19 infection

2020

International audience; Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV (SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and 2015, and SARS-CoV-2 in 2020, have been causing severe and fatal human epidemics. The unpredictability of coronavirus disease-19 (COVID-19) poses a major burden on health care and economic systems across the world. This is caused by the paucity of in-depth knowledge of the risk factors for severe COVID-19, insufficient diagnostic tools for the detection of SARS-CoV-2, as well as the absence of specific and effective drug treatments. While protective humoral and cellular immune responses are usually m…

virusesReviewmedicine.disease_causeDiagnostic toolsSeverity of Illness Index[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityimmune responsehumoral0302 clinical medicineRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesImmunology and AllergyRC254-282Coronavirus[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseasesImmunity Cellular[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesNeoplasms. Tumors. Oncology. Including cancer and carcinogensvirus diseases3. Good healthOncologySevere acute respiratory syndrome-related coronavirus[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology030220 oncology & carcinogenesis[SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunologyMiddle East Respiratory Syndrome Coronavirus[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCovid-19Coronavirus disease 2019 (COVID-19)Sars-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immunology03 medical and health sciencesImmune systemIntensive caremedicineHumans[SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunityHost Microbial Interactionsbusiness.industryRC581-607Protective Factorsbiochemical phenomena metabolism and nutritionmedicine.diseaseimmunityImmunity HumoralClinical trialCoronavirusImmunologyMiddle East respiratory syndromeImmunologic diseases. Allergybusinesscellular030215 immunology
researchProduct

Mortality in COVID-19 disease patients: Correlating Association of Major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (S…

2020

Highlights • In addition to ethnicity, socio-economic factors, prior vaccinations and exposure to other coronaviruses, other factors need to be considered to explain geographical and regional variations in susceptibility, severity of clinical expression of COVID-19 disease and outcomes. • Differences in peptide binding of SARS-CoV-2 variants to MHC class II, but not to MHC class I alleles frequent in individuals with African, Asian or Caucasian descent could be identified. • Single mutations in the wildtype of SARS-CoV-2, the so called B strain or L strain impact on MHC presentation • Most likely there is selective pressure from MHC class II alleles in regard to binding of the ORF8 (L84S) v…

0301 basic medicinecross-reactivityMHC bindingPeptide bindingmedicine.disease_causeAutoimmunity0302 clinical medicine030212 general & internal medicineMutationepitopeautoimmunityGeneral MedicineHLAEuropeviral variantsInfectious DiseasesCoronavirus InfectionsPeptides ; COVID-19 ; Disease association ; Cross-reactivity ; MHC ; T-cells ; Autoimmunity ; Epitope ; Cytokines ; Viral variants ; HLA ; SARS ; SARS-CoV-2 ; MHC bindingMicrobiology (medical)Asia030106 microbiologyPneumonia ViralHuman leukocyte antigenBiologyMajor histocompatibility complexArticlelcsh:Infectious and parasitic diseases03 medical and health sciencesBetacoronavirusMHC class ImedicineHumanslcsh:RC109-216AllelePandemicsAllelesSARSMHC class IISARS-CoV-2T-cellsdisease associationHistocompatibility Antigens Class IHistocompatibility Antigens Class IICOVID-19cytokinesImmunologyAfricabiology.proteinpeptidesMHCInternational Journal of Infectious Diseases
researchProduct

Toning down the 2019-nCoV media hype—and restoring hope

2020

Summary Emerging infectious diseases are an important public health threat and infections with pandemic potential are a major global risk. Although much has been learned from previous events the evidence for mitigating actions is not definitive and pandemic preparedness remains a political and scientific challenge. A need exists to develop trust and effective meaningful collaboration between countries to help with rapid detection of potential pandemic infections and initiate public health actions. This collaboration should be within the framework of the International Health Regulations. Collaboration between countries should be encouraged in a way that acknowledges the benefits that derive …

Pulmonary and Respiratory Medicine2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralCommunicable Diseases EmergingArticleBetacoronavirusHopePandemicHumansMedicinePandemicsbiologySARS-CoV-2business.industryCOVID-19Outbreakbiology.organism_classificationmedicine.diseaseVirologyPneumoniaCoronavirus InfectionsbusinessCoronavirus InfectionsBetacoronavirusThe Lancet Respiratory Medicine
researchProduct

Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-contro…

2020

AbstractBACKGROUNDTreatment of severe Corona Virus Disease 2019 (COVID-19) is challenging. We performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data.METHODSIn this randomized, double-blind, and placebo-controlled trial, we recruited 101 severe COVID-19 patients with lung damage. They were randomly assigned to receive either UC-MSCs (4 × 107 cells per infusion) or placebo on day 0, 3, and 6. The primary endpoint was an altered proportion of whole lung lesion volumes from baseline to day 28. Other imaging outcomes, 6-minute walk test, maximum vital capaci…

medicine.medical_specialtyLungbusiness.industryIncidence (epidemiology)PlaceboGastroenterologyUmbilical cordmedicine.anatomical_structureInternal medicineDiffusing capacityClinical endpointmedicineStem cellAdverse effectbusiness
researchProduct

Host-directed therapies and holistic care for tuberculosis

2020

Pulmonary and Respiratory Medicinemedicine.medical_specialtyTuberculosisbusiness.industryAntitubercular AgentsMEDLINEHolistic HealthMycobacterium tuberculosisHolistic healthmedicine.diseaseHost-Pathogen InteractionsTuberculosis Multidrug-ResistantmedicineHumansIntensive care medicinebusinessHost (network)The Lancet Respiratory Medicine
researchProduct

The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients

2021

Abstract Background/objectives A dysregulated inflammatory profile plays an important role in coronavirus disease-2019 (COVID-19) pathogenesis. Moreover, the depletion of lymphocytes is typically associated with an unfavourable disease course. We studied the role and impact of p53 and deacetylase Sirtuin 1 (SIRT1) on lymph-monocyte homeostasis and their possible effect on T and B cell signalling. Methods Gene expression analysis and flow cytometry were performed on peripheral blood mononuclear cells (PBMC) of 35 COVID-19 patients and 10 healthy donors (HD). Inflammatory cytokines, the frequency of Annexin+ cells among CD3+ T cells and CD19+ B cell subsets were quantified. Results PBMC from …

0301 basic medicineMicrobiology (medical)Male030106 microbiologyInflammationInfectious and parasitic diseasesRC109-216CD19ArticleProinflammatory cytokineBLNK Inflammation03 medical and health sciences0302 clinical medicineSirtuin 1Lymphocyte homeostasismedicineHomeostasisHumans030212 general & internal medicineLymphocytesInterleukin-7 receptorB cellAgedInflammationBLNKbiologySirtuin 1SARS-CoV-2COVID-19p53/SIRT1General MedicineIL-7RMiddle Agedmedicine.anatomical_structureInfectious DiseasesSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICABLNK; COVID-19; IL-7R; inflammation; p53/SIRT1ImmunologyB-cell linkerbiology.proteinCytokinesFemalemedicine.symptomTumor Suppressor Protein p53
researchProduct

An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019

2020

Abstract Increased production of inflammatory cytokines and myeloid-derived suppressor cells occurs in patients with coronavirus disease 2019. These inversely correlated with perforin-expressing natural killer (NK) and CD3+ T cells. We observed a lower number of perforin-expressing NK cells in intensive care unit (ICU) patients compared with non-ICU patients, suggesting an impairment of the immune cytotoxic arm as a pathogenic mechanism.

0301 basic medicineMicrobiology (medical)medicine.medical_treatmentMDSCInflammationchemical and pharmacologic phenomenaNK cellsProinflammatory cytokineNatural killer cell03 medical and health sciences0302 clinical medicineImmune systemmedicineCytotoxic T cellcytotoxic cellcytotoxic cellsbiologybusiness.industryCOVID-19COVID-19; cytotoxic cells; inflammation; MDSC; NK cells030104 developmental biologymedicine.anatomical_structureCytokineInfectious DiseasesPerforinSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAinflammation030220 oncology & carcinogenesisImmunologybiology.proteinMyeloid-derived Suppressor Cellmedicine.symptombusinessClinical Infectious Diseases
researchProduct

Global mortality associated with 33 bacterial pathogens in 2019

2022

Background: Reducing the burden of death due to infection is an urgent global public health priority. Previous studies have estimated the number of deaths associated with drug-resistant infections and sepsis and found that infections remain a leading cause of death globally. Understanding the global burden of common bacterial pathogens (both susceptible and resistant to antimicrobials) is essential to identify the greatest threats to public health. To our knowledge, this is the first study to present global comprehensive estimates of deaths associated with 33 bacterial pathogens across 11 major infectious syndromes. Methods: We estimated deaths associated with 33 bacterial genera or species…

MaleBacteriaSyndromeBacterial InfectionsGeneral MedicineGlobal HealthGlobal Burden of DiseaseRisk FactorsSepsisHumansFemaleMortalityChildAfrica South of the SaharaLancet
researchProduct

Commemorating World TB Day 2020: “IT’S TIME” — It’s time to End the Global TB Epidemic

2020

Microbiology (medical)Susceptibility testingPediatricsmedicine.medical_specialtyTuberculosisbusiness.industryMEDLINEGeneral Medicinemedicine.diseaselcsh:Infectious and parasitic diseasesInfectious DiseasesMedicinelcsh:RC109-216businessInternational Journal of Infectious Diseases
researchProduct

COVID-19: viral–host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection

2020

AbstractBackgroundEpidemiological, virological and pathogenetic characteristics of SARS-CoV-2 infection are under evaluation. A better understanding of the pathophysiology associated with COVID-19 is crucial to improve treatment modalities and to develop effective prevention strategies. Transcriptomic and proteomic data on the host response against SARS-CoV-2 still have anecdotic character; currently available data from other coronavirus infections are therefore a key source of information.MethodsWe investigated selected molecular aspects of three human coronavirus (HCoV) infections, namely SARS-CoV, MERS-CoV and HCoV-229E, through a network based-approach. A functional analysis of HCoV-hos…

0301 basic medicineChemokinevirusesPneumonia ViralGene regulatory networklcsh:MedicineComputational biologyVirus-host interactomemedicine.disease_causeModels BiologicalInteractomeGeneral Biochemistry Genetics and Molecular BiologyTranscriptomePathogenesis03 medical and health sciencesBetacoronavirus0302 clinical medicineViral Envelope ProteinsProtein Interaction MappingmedicineCoronavirus infectionHumansGene Regulatory NetworksPandemicsGeneCoronavirusVirus–host interactomeMembrane GlycoproteinsInnate immune systembiologySARS-CoV-2Researchlcsh:RCOVID-19virus diseasesGeneral Medicinebiochemical phenomena metabolism and nutritionVirus–host interactome ; COVID-19 ; Coronavirus infection ; Spike glycoproteinPhenotyperespiratory tract diseasescoronavirus infection; spike glycoprotein; virus-host interactome030104 developmental biologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisHost-Pathogen Interactionsbiology.proteinSpike glycoproteinCoronavirus InfectionsSignal TransductionJournal of Translational Medicine
researchProduct

Lessons from the COVID-19 Pandemic—Unique Opportunities for Unifying, Revamping and Reshaping Epidemic Preparedness of Europe’s Public Health Systems

2020

Microbiology (medical)2019-20 coronavirus outbreakEconomic growthmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Public healthCOVID-19General Medicinelcsh:Infectious and parasitic diseasesInfectious DiseasesSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAPreparednessPolitical sciencePandemicmedicinelcsh:RC109-216International Journal of Infectious Diseases
researchProduct

Additional file 2 of COVID-19: viral–host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection

2020

Additional file 2: Figure S1. Pairwise distances along 259 full length CoV genomes. In the bottom of picture, indicative gene positioning along CoVs genomes is reported. The list of all considered genomes is reported in Additional file 1: Table S1. Figure S2. 3D structure of S-glycoprotein of SARS-CoV-2 and comparison with the ortholog from HCoV-229E, SARS-CoV, and MERS-CoV. Lateral (a) and superior (b) representation of SARS-CoV-2 S-glycoprotein, deducted for the sequence of patient INMI1 (MT066156.1). Each subunit chain has a different color. Structure comparison of S-glycoprotein subunit between: HCoV-229E and SARS-CoV-2, in purple and blue respectively (c); SARS-CoV and SARS-CoV-2, in r…

virusesvirus diseasesrespiratory systembiochemical phenomena metabolism and nutritionrespiratory tract diseases
researchProduct

Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases

2020

Abstract Background SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to SARS-CoV-2 play a crucial role in determining the clinical course after first infection. Immunological studies have focussed on patients with moderate to severe disease, demonstrating excessive inflammation in tissues and organ damage. We have studied the individual response to SARS-CoV-2 of asympromatic, mild and severe COVID-19 patients in order to investigate the role of innnate and adaptive immunity in determining the clinical course after first infection. Methods To understand the basis of th…

0301 basic medicineAdultMalelcsh:Immunologic diseases. AllergyImmunologyInflammationDiseaseAdaptive Immunitymedicine.disease_causeAntibodies ViralAsymptomaticSeverity of Illness IndexSerology03 medical and health sciences0302 clinical medicineImmune systeminnate and adaptiveimmune responsemedicineHumansImmunology and AllergyantibodiesNK cellOriginal ResearchCoronavirusB cellsbiologybusiness.industrySARS-CoV-2MonocyteSettore BIO/12COVID-19antibodies; B cells; COVID-19; innate and adaptiveimmune response; monocytes; NK cell; SARS-CoV-2Acquired immune systemImmunity InnateImmunoglobulin AKiller Cells Natural030104 developmental biologymedicine.anatomical_structureImmunoglobulin MSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisImmunologybiology.proteinFemalemedicine.symptomAntibodybusinesslcsh:RC581-607monocytes
researchProduct

Additional file 1 of COVID-19: viral–host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection

2020

Additional file 1: Table S1. List of accession numbers of H-CoV. Table S2. List of genes selected by RWR algorithm for HCoV-229E, along with proximity score. Table S3. List of genes selected by RWR algorithm for SARS-CoV, along with proximity score. Table S4. List of genes selected by RWR algorithm for MERS-CoV, along with proximity score.

researchProduct

Burden of non-communicable diseases among adolescents aged 10-24 years in the EU, 1990-2019: a systematic analysis of the Global Burden of Diseases S…

2022

Background: Disability and mortality burden of non-communicable diseases (NCDs) have risen worldwide; however, the NCD burden among adolescents remains poorly described in the EU. Methods: Estimates were retrieved from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. Causes of NCDs were analysed at three different levels of the GBD 2019 hierarchy, for which mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) were extracted. Estimates, with the 95% uncertainty intervals (UI), were retrieved for EU Member States from 1990 to 2019, three age subgroups (10–14 years, 15–19 years, and 20–…

Malemortality burdenAdolescentRJRJ101CareGlobal Burden of DiseaseLife ExpectancyRJ101 Child Health. Child health servicesSDG 3 - Good Health and Well-beingRA04213123 Gynaecology and paediatricsRisk FactorsRA0421 Public health. Hygiene. Preventive MedicineDevelopmental and Educational PsychologyHumansDisabled PersonsNoncommunicable DiseasesFutureDeterminantsMCCDisabilityPublic Health Global Health Social Medicine and EpidemiologyBurden of non-communicable diseases among adolescents aged 10–24 years in the EU 1990–2019: a systematic analysis of the Global Burden of Diseases Study 20193rd-DASDisability; mortality burdenFolkhälsovetenskap global hälsa socialmedicin och epidemiologin/aHealthPediatrics Perinatology and Child HealthFemaleRA
researchProduct